Company intelligence / Profile preview

Amakem

Diepenbeek, Belgiumuk.marketscreener.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Amakem's lead candidate AMA0076 is a novel, highly potent Rho Kinase (ROCK) inhibitor targeted at the treatment of glaucoma. It has been designed to allow for high localized dosing in the eye combined with low systemic exposure[3][5].

Therapeutic areas: OphthalmologyGastroenterologyPulmonology
Modalities: Small molecules (kinase inhibitors)
Industry: Biotech

Drug pipeline

3 assets

AMA0076

2 more assets in the full pipeline.

Request access →

Partnerships

University of Leuven Hospital (Ophthalmology Research Center)[3]

Beyond the preview

Go deeper on Amakem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amakem.

Explore the full profile